Navigation Links
BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
Date:5/1/2008

s for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, futur
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical to present at EQUITIES Conference
2. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
3. BioMS Medical to present at BioCentury Conference
4. BioMS Medical Announces 2007 Year End Results
5. BioMS Medical to present at BIO CEO & Investor Conference
6. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces third quarter 2007 results
10. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
11. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015 With recent advancements ... you the government, major companies are getting into the ... setting future mandates for renewable energy production, many homeowners ... , Solara Power is a new solar distribution company ... available that allow qualifying homeowners to enjoy the benefits ...
(Date:3/30/2015)... March 30, 2015  NuGene International, Inc. ("NuGene") ... NuGene BioPharma, Inc. has added another internationally recognized ... Guan is an internationally recognized researcher in bio-inspired ... education at Peking University, China ... the University of North Carolina, Chapel Hill. Following ...
(Date:3/30/2015)... OTTAWA , March 30, 2015 /CNW/ - A ... today on the salaries and demographic profiles of new ... "Opening the Door – Building Careers for New Grads ... Canada,s Research-Based Pharmaceutical Companies (Rx&D) and features ... federal Career Focus wage subsidy program from 2013 to ...
(Date:3/30/2015)... England , March 30, 2015 ... developing novel biological drugs to treat cancer, viral ... of Professor Sir John Bell , the ... Chairman of the Office for the Strategic Coordination ... with immediate effect.      (Photo: ...
Breaking Biology Technology:Solara Power Announces Residential Solar Power with No Up-Front Fees 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
... NVAX ) and the University ... preclinical study of a Respiratory Syncytial Virus ("RSV"),vaccine ... from the, University of Massachusetts Medical School ... Paramyxovirus vaccines incorporating,certain Virus-Like-Particles ("VLPs"). This vaccine ...
... Calif., Dec. 9 BioMarin Pharmaceutical,Inc. (Nasdaq: ... its partner Merck Serono, a division,of Merck ... for,Kuvan(R) (sapropterin dihydrochloride) for the treatment of,hyperphenylalaninemia ... patients,from the European Commission. Merck Serono ...
... Corporation today announced favorable results from a Phase 1 ... candidates, for use during urological surgery. , ... of OMS201 enrolled patients undergoing endoscopic removal of urinary ... and safety of the drug product. The pharmacokinetic data ...
Cached Biology Technology:NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 2NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 3NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 4Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group ... NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one ... feedback on their experience with the Wocket in multiple scenarios ... CVS, Whole Foods and other retailers, making both debit and ... Tuttle also says, "If the company meets their plans ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... and toes (metatarsals) and can be restricted in growth ... called brachydactyly type E (Greek for short fingers). Three ... group of Professor Friedrich C. Luft at the Experimental ... the Charit Medical Faculty and the Max Delbrck Center ...
... MIAMI November 5, 2012 -- A new study by ... Marine & Atmospheric Science uses Interferometric Synthetic Aperture Radar (InSAR) ... volcanoes in Indonesia,s west Sunda arc. Led by geophysicist Estelle ... that several volcanoes did in fact ,inflate, prior to eruptions ...
... Biomedical Research Institute scientists in San Antonio have developed ... for bioterror threats and accelerate the application of countermeasures., ... molecular magnets that bind to and hold on ... That will enable countermeasures to be selected and ...
Cached Biology News:New findings on gene regulation and bone development 2New findings on gene regulation and bone development 3New findings on gene regulation and bone development 4Taking the 'pulse' of volcanoes using satellite images 2Texas Biomed reports faster, more economical method for detecting bioterror threats 2
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
dithiothreitol, sulfhydryl reducing agent, C4H10O2S2; MW: 154.24, 97% pure (minimum), CAS No: 27565-41-9, store at -20 C ...
... Nucleon HT, 1 kit. Facilitates the ... paraffin-embedded sections and hard tissue requiring proteinase ... high quality DNA from 50 preparations of ... Category: DNA/RNA Synthesis & Purification, Purification and ...
Biology Products: